Compare BioNano Genomics Inc (BNGO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs JetBlue Airways Corporation — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while JetBlue Airways Corporation trades at $5.86 (market cap $2.19B). The key difference: JetBlue Airways Corporation is far larger — about 160.3× BioNano Genomics Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | JBLU | |
|---|---|---|
Market Cap | $13.66M | $2.19B |
Sector | Health | Industrials |
52-Week High | $4.92 | $6.46 |
52-Week Low | $1.06 | $4.03 |
Enterprise Value | $16.26M | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
JetBlue (JBLU) trades at $5.855, up 3.81% today, with a bullish technical signal from moving averages but mixed earnings history including a recent Q2 2026 beat. The company shows negative profitability with a net income margin of -9.32% and ROE of -44.36%, while valuation ratios like P/S of 0.23 suggest potential undervaluation. Recent news highlights analyst downgrades and operational challenges from high fuel costs, alongside strategic initiatives like new fare structures and lounge awards.
Outlook remains cautious due to persistent losses and external pressures, but cost management and revenue growth initiatives offer recovery potential. Key risks include fuel price volatility and competitive intensity, while analyst consensus is neutral with a $5.18 price target slightly below current levels, indicating limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
